Literature DB >> 18050071

Lumbar radiculopathy due to unilateral facet hypertrophy following lumbar disc hernia operation: a case report.

Fatih Kökeş1, Ahmet Günaydin, Ahmet Aciduman, Mehmet Kalan, Halit Koçak.   

Abstract

OBJECTIVE: To present a radiculopathy case due to unilateral facet hypertrophy developing three years after a lumbar disc hernia operation. CASE REPORT: A fifty two-year-old female patient, who had been operated on for a left L5-S1 herniated lumbar disc three years ago, was hospitalized and re-operated with a diagnosis of unilateral facet hypertrophy. She had complaints of left leg pain and walking restrictions for the last six months. Left Straight Leg Raising test was positive at 40 degrees , left ankle dorsiflexion muscle strength was 4/5, left Extensor Hallucis Longus muscle strength was 3/5, and left Achilles reflex was hypoactive. Lumbar spinal Magnetic Resonance Imaging revealed left L5-S1 facet hypertrophy. RESULTS AND
CONCLUSIONS: Lumbar radiculopathy due to lumbar facet hypertrophy is a well-known neurological condition. Radicular pain develops during the late postoperative period following lumbar disc hernia operations that are often related to recurrent disc herniation or to formation of post-operative scar tissue. In addition, it can be speculated that unilateral facet hypertrophy, which may develop after a disc hernia operation, might also be one of the causes of radiculopathy.

Entities:  

Mesh:

Year:  2007        PMID: 18050071

Source DB:  PubMed          Journal:  Turk Neurosurg        ISSN: 1019-5149            Impact factor:   1.003


  2 in total

1.  Neglected knowledge: Asymmetric features of lumbar disc disease.

Authors:  Ayhan Kanat; Ugur Yazar; Bulent Ozdemir; Hizir Kazdal; Mehmet Sabri Balik
Journal:  Asian J Neurosurg       Date:  2017 Apr-Jun

2.  Cervical radiculopathy due to disc herniation with adjacent facet hypertrophy: case report.

Authors:  Hitoshi Yamahata; Muneyoshi Yasuda; Tatsuro Aoyama; Koji Osuka; Kazunori Arita; Masakazu Takayasu
Journal:  Neurol Med Chir (Tokyo)       Date:  2014-01-28       Impact factor: 1.742

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.